ClinicalTrials.gg
RecruitingNCT06774014Updated Feb 28, 2025

Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences

An observational study in Diabetes Mellitus Type 2, Heart Failure and HFrEF - Heart Failure With Reduced Ejection Fraction, sponsored by University of Leeds. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by University of Leeds · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom — 58 open to participants now, 74 under way, 20 of them phase 3. Diabetes Mellitus, Type 2 · United Kingdom.

Planned enrollment
37th of 78
600 · median 578
Started
2025
with 14 others
Observational
78 of 573
17 open now
Primary completion
2030-01
later than 65 of 73 live
Registered
539th of 573
by date

Among the 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, this one is the 37th largest by planned enrollment of the 78 observational ones that give a count, is one of 15 that started in 2025, is one of 78 observational ones, reaches primary completion later than 65 of the 73 other live ones, and was the 539th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

58 of the 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 573 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, or all of them as a file.
02

Study summary

This will be an observational study to explore differences in pathophysiology between groups of people with and without heart failure (HF) (reduced and preserved ejection fraction) and with and without diabetes mellitus (DM) with a particular focus on cross-talk (fat, muscle, vascular tissue and the heart). The investigators will invite 600 people to partcipate (100 with HFrEF+DM, 100 with HFpEF+DM, 100 with HFpEF-DM, 100 with HFrEF-DM, 100 with DM, 100 without either HR or DM). Special heart scans, exercise testing, blood testing, testing of the automatic nervous system will be performed and in some, samples of fat and muscle and endothelial cells will be collected.

These data will be used to create a cohort of well phenotyped patients with a variety of comprehensively collected clinical information, a cell atlas, and a comprehensive assessment of metabolomics, proeomics and cross-talk in between tissues, allowing comparisons between each group.

Read the detailed description

Heart failure is a leading cause of mortality and morbidity worldwide, and is characterized by symptoms such as shortness of breath, peripheral oedema and impaired exercise capacity due to structural or functional heart disease. The condition is associated with impaired longevity, high levels of morbidity (poor quality of life) and enormous costs for the healthcare system. In the western world, approximately 1-2% of the population suffer from heart failure, increasing to over 10% of people over the age of 70. The prognosis of patients with severe heart failure is similar to that of patients with cancer.

Diabetes mellitus is reaching pandemic proportions across the globe. A condition previously characterised simply as a relative or absolute deficiency of insulin and diagnosed by elevated sugar levels in the bloodstream, it is now much better understood as a syndrome of impaired glucose tolerance accompanied by a range of metabolic abnormalities that can be observed in all tissues of the body. This metabolic remodelling is accompanied by higher risks of chronic disease particularly cardiovascular disease including atherosclerosis but also, even in the absence of coronary artery disease, a considerable increase in the risk of heart failure.

These two morbid and life-limiting illnesses commonly occur together, each worsening the other in a synergistic relationship that leads to greater symptoms, resistance to therapies and shorter longevity.

Further detail on how these diseases interact is urgently required. However, in addition to understanding the clinical impacts on patients, in order to focus existing therapies and develop new options, it is necessary to understand how these diabetes mellitus an heart failure interact at a metabolic level, which cellular-based pathways are affected and how these lead to abnormal cellular function, and thereby to tissue and organ dysfunction. Further understanding of how communication between tissues contributes to the overall pathophysiology is required.

The present investigation will therefore be a single-centre non-randomised, observational study involving an unselected but highly phenotyped cohort of patients with and without heart failure and with and without type 2 diabetes mellitus and controls without disease. Patients will be recruited from heart failure and diabetes clinics and controls will be identified from these patients' carers and their relatives through direct contact and advertisements in outpatient departments.

Participants will undergo cardiac ultrasound, exercise testing, assessments of lung function, non-invasive haemodynamics, autonomic function, hand and leg muscle strength, and lung function assessment along with blood testing, longer term glucose monitoring and blood sampling. A small sample of fat and muscle will be collected. A subgroup will undergo an MRI scan of the heart and their thigh muscles. Participants' involvement will end at that point although they will continue to be monitored using their digital records on an annual basis for up to 10 years to gain information on the prognostic value of the metabolic and haemodynamic testing.

Tissue and blood samples will be coded and stored in a Human Tissue Authority-approved freezer until analysis following which they will be related to clinical variables with the aim of identifying mechanisms by which metabolic disease (in this case diabetes mellitus) influences the progression of heart failure with the long term objective of informing the development of more effective treatment strategies.

The present investigation will allow the investigators to advance the understanding of how metabolic disease and heart failure interact with the goal of developing targeted interventions that could open new treatment avenues.

03

Conditions studied

  • Diabetes Mellitus Type 2
  • Heart Failure
  • HFrEF - Heart Failure With Reduced Ejection Fraction
  • HFpEF - Heart Failure With Preserved Ejection Fraction

Keywords

  • Crosstalk
  • Metabolomics
  • Proteomics
  • Fat
  • Skeletal muscle
  • Vascular function
  • Autonomic function
  • Endothelial function
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

People attending heart failure clinics, diabetes clinics (either secondary or primary care) or control subjects attending hospital with relatives or accumulated from the community by word of mouth or advertisement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Ability to provide written
  • Persons who are legally competent and mentally able to follow the instructions of the study staff

Exclusion criteria

Exclusion Criteria:

  • Anaemia \<8 mg/dl
  • Patients with acute infectious diseases (e.g. pneumonia)
  • Patients with heart failure due to sepsis
  • People with acute myocardial ischemia, which is manifested, for example, by angina pectoris or changes under stress
  • Patients with acute liver or kidney failure or severe (\<1.0)
  • Pregnant and breastfeeding women
  • People who are institutionalized on official or court orders
  • People who are dependent or employed by the sponsor or investigator
  • Taking study medication (of an drug) 30 days before the start of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
600 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • HFrEF-DM

    People with heart failure due to reduced ejection fraction without diabetes mellitus

  • HFrEF+DM

    People with heart failure due to reduced ejection fraction who also have diabetes mellitus

  • HFpEF-DM

    People with heart failure with preserved ejection fraction without diabetes mellitus

  • HFpEF+DM

    People with heart failure with preserved ejection fraction who also have diabetes mellitus

  • DM

    People who have diabetes mellitus but do not have heart failure

  • Control

    People who have neither heart failure nor diabetes mellitus

06

What researchers measure

Primary outcomes

  1. Study primary endpoint

    Are there differences in skeletal muscle cellular metabolism assessed by mass spectrometry-based metabolomics and lipidomics between the two phenotypes of heart failure compared with controls and what influence does diabetes mellitus have?

    Time frame: 5 years

Secondary outcomes

  1. Secondary outcome 1

    How does T2DM influence intercellular communication to promote the progression of HF

    Time frame: 5 years

  2. Secondary outcome 2

    Are there correlations between abnormalities in these cells and cardiac abnormalities, patient symptoms and clinical outcomes?

    Time frame: 5 years

  3. Secondary outcome 3

    What metabolic pathways are abnormal in people with heart failure, diabetes mellitus and both?

    Time frame: 5 years

  4. Secondary outcome 4

    Can we identify using metabolomics, a substrate or compound that underlies the metabolic abnormalities?

    Time frame: 5 years

  5. Secondary outcome 5

    Does organ 'cross-talk' have a negative influence on the functions of skeletal muscle, fat, platelets and clotting function, and cardiac function?

    Time frame: 5 years

  6. Secondary outcome 6

    Is autonomic activation reflected in metabolic abnormalities in HFrEF or HFpEF?

    Time frame: 5 years

  7. Secondary outcome 7

    Is lung function, especially that of the diaphragm and smooth muscle of the medium-sized bronchioles reflective of the metabolic abnormalities and how do these relate to the two major HF phenotypes?

    Time frame: 5 years

  8. Secondary outcome 8

    Do the laboratory data describing muscle and fat metabolomics relate to clinical variables and prognosis?

    Time frame: 5 years

  9. Secondary outcome 9

    Is cardiac contractility impairment as measured by cardiac magnetic resonance related to the tissue-based metabolic abnormalities and can we identify different subgroups of contractile function within the heart failure and diabetes groups.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — An anonymised version of the database and the samples will be available to other researchers including outside of the University of Leeds in response to a reasonable request and confirmation of appropriate data protection policies and a mutual data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 6 months after the end of the study

Access criteria: Requests to be made to the Trial Management Group

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Jan 2030, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 14, 2025
StartActual
Feb 26, 2025
Primary completionEst.
Jan 31, 2030
CompletionEst.
Jan 31, 2030
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06774014
Responsible party
Klaus K Witte, MD (Senior Lecturer in Cardiology, University of Leeds) — Principal investigator
First posted
Jan 14, 2025
Start date
Feb 26, 2025
Primary completion
Jan 31, 2030 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Feb 28, 2025

Study contacts

Klaus Witte, MD
Contact
k.k.witte@leeds.ac.uk
007768254073

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion